First person profile: Dennis J. Slamon, MD, PhD - Printz.
About Dr. Dennis J. Slamon, MD Dr. Dennis J. Slamon is an oncologist in Santa Monica, California and is affiliated with multiple hospitals in the area. He has been in practice for more than 20 years.
Slamon, MD PhD, University of California, Los Angeles: Thank you Sharon. So I have got just a few slides to try and put into point some of the things that have been raised, but—but coming out of the gate, I’ll say something that I’ve said to many of you in the past. And that is to repeat—never, never, never stop holding our feet to the fire in terms of what you want to see and—and.
DR SLAMON: The BCIRG 006 trial (Slamon 2006) had a nonanthracycline arm. The study demonstrated that cardiac dysfunction in patients who received trastuzumab and anthracyclines, even when trastuzumab was administered after the anthracycline, increased fourfold to fivefold (1.1). This toxicity is certainly not short and transient, as people have been saying — a few weeks or months — it’s.
Mentors: Dennis J. Slamon, MD, PhD, Richard S. Finn, MD, William Tap, MD, and Melinda S. Epstein, PhD Projects: 1) Rational Development of anti-Epidermal Growth Factor Receptor Targeted Therapeutics used in the Treatment of Pancreatic Cancer, 2) The role HER-2 and Vascular Endothelial Growth Factor alpha in neo-angiogenesis.
Dennis Slamon, MD, PhD. Director of clinical and translational research at the Jonsson Cancer Center, Dr. Slamon and his colleagues conducted the laboratory and clinical research that led to the development of Herceptin, the first targeted cancer therapy approved by the FDA.
Dennis J. Slamon, MD, PhD. Ribociclib (Kisqali) with fulvestrant (Faslodex) resulted in a clinically significant overall survival (OS) benefit compared with placebo in postmenopausal patients with hormone receptor (HR) positive, HER2-negative advanced breast cancer, according to findings from the phase III MONALEESA-3 trial presented at the 2019 ESMO Congress. 1.
Dennis J. Slamon, MD, PhD, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Eli Lilly, Novartis Pharmaceuticals Corporation Received grants for clinical research from: Novartis Pharmaceuticals Corporation, Pfizer Inc., Syndax.